Award of Shares under Share Incentive Plan

Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of surgical endoscopy, implemented an HMRC approved Share Incentive Plan ("SIP") during 2020 which is available to all of the Company's UK based employees, including Directors.

Under the SIP, shares are acquired in four ways:

• Partnership Shares where an employee can spend up to a £1,800 or 10% of their pre-tax income, whichever is the lower;
• Matching Shares, where Creo can give up to two free Matching Shares for each Partnership Share bought. The plan requires employees to remain in employment for three years to benefit from the Matching Shares;
• Free Shares, where Creo can give up to £3,600 of free shares in any tax year; and
• Dividend Shares where additional shares can be bought with any dividends paid.

The Company has been notified that Fiduchi Trustees (UK) Limited, the independent trustee of the SIP, acquired, in accordance with the SIP's rules and on behalf of SIP participants, 171,050 ordinary shares in the Company ("Ordinary Shares"), at a price of £0.435 per Ordinary Share on 15 January 2024 to meet its obligations under the SIP. Under the terms of the SIP, the Company is required to issue to the SIP, two Ordinary Shares in the Company for each Partnership Share purchased, being 225,024 new Ordinary Shares (having taken into account 117,076 ordinary shares held by the Trust which were previously allocated to employees who ceased employment before the shares had vested). These new Ordinary Shares will be held by Fiduchi Trustees (UK) Limited as trustee of the SIP.

Craig Gulliford, Richard Rees and Christopher Hancock, executive directors of the Company (the "Participating Directors") have received Partnership Shares at a price of £0.435 per share and Matching Shares at a price of £0.001 per share in accordance with terms of the SIP (the "Transaction"). Following this the Participating Directors' shareholdings in the Company are as set out in the table below:

Accordingly, the Company announces that it has made an application for 225,024 new Ordinary Shares to be admitted to trading on AIM. It is expected that admission will take place on 26 January 2024. Following the allotment and issue, the Company's issued share capital consists of 361,476,442 Ordinary Shares. The Company does not hold any shares in Treasury. As such the total number of shares in issue with voting rights is 361,476,442.

Total Voting Rights (TVR)

The above figure of 361,476,442 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

[1] This figure includes 1,000,000 shares held by Mr Gulliford’s wife.

• Description of the financial instrument Ordinary Shares
• Nature of the transaction Purchase of Ordinary Shares under Share Incentive Plan
• Price(s) and volume(s) Prices Volume(s) £0.435 2,069
• Aggregated information Aggregated volume Price N/A - Single transaction
• Date of the transaction 2024-01-19 GMT
• Place of the transaction London Stock Exchange

1. Details of PDMR

• Name Craig Gulliford
• Position / status CEO
• Initial notification / amendment Initial notification
• Description of the financial instrument Ordinary Shares
• Nature of the transaction Award of Ordinary Shares under Share Incentive Plan
• Price(s) and volume(s) Prices Volume(s) £0.001 4,138
• Aggregated information Aggregated volume Price N/A - Single transaction
• Date of the transaction 2024-01-19 GMT
• Place of the transaction London Stock Exchange

1. Details of PDMR

• Name Richard Rees
• Position / status CFO
• Initial notification / amendment Initial notification
• Description of the financial instrument Ordinary Shares
• Nature of the transaction Purchase of Ordinary Shares under Share Incentive Plan
• Price(s) and volume(s) Prices Volume(s) £0.435 2,069
• Aggregated information Aggregated volume Price N/A - Single transaction
• Date of the transaction 2024-01-19 GMT
• Place of the transaction London Stock Exchange

1. Details of PDMR

• Name Richard Rees
• Position / status CFO
• Initial notification / amendment Initial notification
• Description of the financial instrument Ordinary Shares
• Nature of the transaction Award of Ordinary Shares under Share Incentive Plan
• Price(s) and volume(s) Prices Volume(s) £0.001 4,138
• Aggregated information Aggregated volume Price N/A - Single transaction
• Date of the transaction 2024-01-19 GMT
• Place of the transaction London Stock Exchange

1. Details of PDMR

• Name Christopher Hancock
• Position / status CTO
• Initial notification / amendment Initial notification
• Description of the financial instrument Ordinary Shares
• Nature of the transaction Purchase of Ordinary Shares under Share Incentive Plan
• Price(s) and volume(s) Prices Volume(s) £0.435 2,069
• Aggregated information Aggregated volume Price N/A - Single transaction
• Date of the transaction 2024-01-19 GMT
• Place of the transaction London Stock Exchange

1. Details of PDMR

• Name Christopher Hancock
• Position / status CTO
• Initial notification / amendment Initial notification
• Description of the financial instrument Ordinary Shares
• Nature of the transaction Award of Ordinary Shares under Share Incentive Plan
• Price(s) and volume(s) Prices Volume(s) £0.001 4,138
• Aggregated information Aggregated volume Price N/A - Single transaction
• Date of the transaction 2024-01-19 GMT
• Place of the transaction London Stock Exchange